ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020
Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Presence of SARS-CoV-2 and Its Entry Factors in Oral Tissues and Cells: A Systematic Review.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Histamine receptors and COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Pooled it
- Intranasal Chlorpheniramine for Early Symptomatic Treatment of COVID-19 and the Impact on Long-COVID.Cureus · 2025Review
- POGZ targeted by LINC01355/miR-27b-3p retards thyroid cancer progression via interplaying with MAD2L2.3 Biotech · 2025Article
- Deciphering GABBR1-centered drug targets to fight viral infection with preexisting diabetes.Acta biochimica et biophysica Sinica · 2023Article
- Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation.Acta biochimica et biophysica Sinica · 2023Article
- TAS2R supports odontoblastic differentiation of human dental pulp stem cells in the inflammatory microenvironment.Stem cell research & therapy · 2022Article
- New values of a type 2 taste receptor TAS2R14 in thyroid cancer.Acta biochimica et biophysica Sinica · 2022Article
- Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022Article
- Asymptomatic Transmissibility Calls for Implementing a Zero-COVID Strategy to End the Current Global Crisis.Frontiers in cellular and infection microbiology · 2022Article
- Psychotropics and COVID-19: An analysis of safety and prophylaxis.L'Encephale · 2021Article
- Article
- Analysis of single nucleotide polymorphisms between 2019-nCoV genomes and its impact on codon usage.Gene reports · 2021Article
- Chloroquine and COVID-19: role as a bitter taste receptor agonist?New microbes and new infections · 2021Article
- Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.Bioscience reports · 2021Article
- Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.Computers in biology and medicine · 2020Article
- Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients.Journal of medical virology · 2020Article
- Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.Gastroenterology · 2020Article
- Publishing coronavirology: Peering into peer(less?) review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The sudden outbreak of COVID-19 has led to more than seven thousand deaths. Unfortunately, there are no specific drugs available to cure this disease. Type 2 taste receptors (TAS2Rs) may play an important role in host defense mechanisms. Based on the idea of host-directed therapy (HDT), we performed a negative co-expression analysis using big data of 60 000 Affymetrix expression arrays and 5000 TCGA data sets to determine the functions of TAS2R10, which can be activated by numerous bitter substances. Excitingly, we found that the main functions of TAS2R10 involved controlling infectious diseases caused by bacteria, viruses, and parasites, suggesting that TAS2R10 is a key trigger of host defense pathways. To quickly guide the clinical treatment of 2019-nCoV, we searched currently available drugs that are agonists of TAS2Rs. We identified many cheap, available, and safe medicines, such as diphenidol, quinine, chloroquine, artemisinin, chlorpheniramine, yohimbine, and dextromethorphan, which may target the most common symptoms caused by 2019-nCoV. We suggest that a cocktail-like recipe of existing bitter drugs may help doctors to fight this catastrophic disease and that the general public may drink or eat bitter substances, such as coffee, tea, or bitter vegetables, to reduce the risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.